media overlooking COVID treatments AT-527 oral antiviral demonstrated in phase 3 clinical trials to be effective against COVID-19 AND varian
media focuses on vaccines and not treatments
ATEA Pharmaceuticals (AVIR)
A new company and THE leading candidate for an oral antiviral demonstrated effective against COVID-19 to reduce the viral load. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus and variants. Phase 3 clinical results due 8/1212/21. Last stage before filing for FDA approval. Emergency approval needed
742nd
ranked
Slatesquarry
shared this idea